MétodosĮl estudio MERCED es un ensayo prospectivo y aleatorizado que incluye a 33 mujeres posmenopáusicas con enfermedad coronaria. El objetivo del estudio es determinar el efecto del raloxifeno en: a) la función endotelial, y b) las vías de la coagulación y la fibrinolisis en mujeres posmenopáusicas con enfermedad coronaria. Estudios recientes han generado controversia respecto al riesgo tromboembólico del raloxifeno. En mujeres posmenopáusicas, se ha propuesto un efecto beneficioso en la función endotelial del modulador selectivo del receptor estrogénico raloxifeno, aunque sus efectos en mujeres con cardiopatía isquémica establecida no han sido estudiados plenamente. La modulación del tono vascular es uno de los efectos estrogénicos más relevantes. Further studies are required to determine whether thrombotic risk is associated with specific clinical characteristics or subgroups of postmenopausal women with cardiovascular disease. In the MERCED trial, no increased thrombotic risk was observed, but a decreased thrombotic and fibrinolytic activity was observed with raloxifene. The present study provides evidence that in postmenopausal women with demonstrated endothelial dysfunction and ischemic heart disease, mid-term treatment with raloxifene does not affect endothelial function. 0.94, P<.05) and plasmin/antiplasmin complexes (211 vs. Treatment with raloxifene was associated to decreased levels of fibrinogen (3.41 vs. Resultsįlow-mediated dilatation was severely impaired in the study population, and raloxifene had no effect on endothelial function. Assessment of vascular function and biologic parameters related to coagulation pathways were conducted at various pre-established time-points. Raloxifene treatment was administered for a 3-month period, according to a double-blind crossover design.
Thirty-three postmenopausal women with ischemic heart disease were enrolled in the study.
STACHROM AT III STAGO NOTICE TRIAL
The MERCED trial was a prospective, randomized clinical trial. The aim of the study was to assess the effect of raloxifene on: a) endothelial function and b) coagulation and fibrinolysis pathways. In addition, recent trials have generated controversy regarding thromboembolic risk with raloxifene use. However, its effects in women with established cardiovascular disease have not been fully elucidated.
A beneficial effect on endothelial function in postmenopausal women has also been proposed for the selective estrogen receptor modulator raloxifene. Modulation of vascular tone is one of the most relevant estrogen effects.
0 kommentar(er)
